Suppr超能文献

骨标志物的临床应用:变异性带来的挑战。

Clinical use of bone markers: a challenge to variability.

作者信息

Filella Xavier, Guañabens Núria

机构信息

Servicio de Bioquímica y Genética Molecular (CDB), Hospital Clinic, IDIBAPS, Barcelona, Spain.

Servicio de Reumatología, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.

出版信息

Adv Lab Med. 2023 Aug 28;5(1):7-14. doi: 10.1515/almed-2023-0092. eCollection 2024 Mar.

Abstract

Bone markers are a group of substances released into circulation during bone formation and/or resorption. These substances can be measured in blood and urine to obtain information about metabolic bone disorders. This review provides an insight into factors influencing bone marker variability and describes different approaches to minimize variability and interpret results appropriately. Variability in bone marker concentrations results from biological and analytical variability across assays. Other influencing factors include gender, age, physical exercise, circadian rhythm, and diet. The multiplicity of influencing factors hinders the establishment of accurate reference values. Gaining a deep understanding of bone marker variability is the first step to ascertain their clinical usefulness. Bone marker variability can be minimized by controlling as many variables as it is possible and through the standardization of patient preparation and sample collection and handling.

摘要

骨标志物是在骨形成和/或骨吸收过程中释放到循环系统中的一组物质。这些物质可以在血液和尿液中进行检测,以获取有关代谢性骨病的信息。本综述深入探讨了影响骨标志物变异性的因素,并描述了尽量减少变异性并正确解释结果的不同方法。骨标志物浓度的变异性源于不同检测方法的生物学和分析变异性。其他影响因素包括性别、年龄、体育锻炼、昼夜节律和饮食。多种影响因素阻碍了准确参考值的建立。深入了解骨标志物变异性是确定其临床实用性的第一步。通过尽可能控制多个变量,并对患者准备、样本采集和处理进行标准化,可以将骨标志物变异性降至最低。

相似文献

1
Clinical use of bone markers: a challenge to variability.
Adv Lab Med. 2023 Aug 28;5(1):7-14. doi: 10.1515/almed-2023-0092. eCollection 2024 Mar.
7
Reference intervals for serum concentrations of three bone turnover markers for men and women.
Bone. 2013 Dec;57(2):399-404. doi: 10.1016/j.bone.2013.09.010. Epub 2013 Sep 27.
8
Current use of bone turnover markers in the management of osteoporosis.
Clin Biochem. 2022 Nov-Dec;109-110:1-10. doi: 10.1016/j.clinbiochem.2022.09.002. Epub 2022 Sep 9.
9
Clinical usefulness of bone turnover marker concentrations in osteoporosis.
Clin Chim Acta. 2017 Apr;467:34-41. doi: 10.1016/j.cca.2016.06.036. Epub 2016 Jun 30.
10
Contribution of bone turnover markers to the variation in bone mineral density: a study in Vietnamese men and women.
Osteoporos Int. 2018 Dec;29(12):2739-2744. doi: 10.1007/s00198-018-4700-9. Epub 2018 Sep 8.

引用本文的文献

本文引用的文献

1
Bone turnover markers to monitor oral bisphosphonate therapy.
Cleve Clin J Med. 2023 Jan 3;90(1):26-31. doi: 10.3949/ccjm.90a.22002.
2
Bone Turnover Markers: Basic Biology to Clinical Applications.
Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031.
3
New Emerging Biomarkers for Bone Disease: Sclerostin and Dickkopf-1 (DKK1).
Calcif Tissue Int. 2023 Feb;112(2):243-257. doi: 10.1007/s00223-022-01020-9. Epub 2022 Sep 27.
4
Current use of bone turnover markers in the management of osteoporosis.
Clin Biochem. 2022 Nov-Dec;109-110:1-10. doi: 10.1016/j.clinbiochem.2022.09.002. Epub 2022 Sep 9.
5
The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations.
Calcif Tissue Int. 2023 Feb;112(2):258-270. doi: 10.1007/s00223-022-00987-9. Epub 2022 Jun 4.
6
A Systematic Review of the Circadian Rhythm of Bone Markers in Blood.
Calcif Tissue Int. 2023 Feb;112(2):126-147. doi: 10.1007/s00223-022-00965-1. Epub 2022 Mar 19.
7
Low serum osteocalcin levels are associated with diabetes mellitus in glucocorticoid treated patients.
Osteoporos Int. 2022 Mar;33(3):745-750. doi: 10.1007/s00198-021-06167-z. Epub 2021 Sep 24.
8
An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk.
Front Physiol. 2021 Mar 9;12:632260. doi: 10.3389/fphys.2021.632260. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验